High pH protein refolding methods

US10065987B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10065987-B2
Application numberUS-201414766848-A
CountryUS
Kind codeB2
Filing dateFeb 11, 2014
Priority dateFeb 12, 2013
Publication dateSep 4, 2018
Grant dateSep 4, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are methods for refolding denatured protein (e.g., from inclusion bodies) that do not require the use of a denaturing agent. Exemplary methods use a high pH for solubilizing denatured protein, followed by a decrease in pH for refolding the proteins.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for refolding a denatured protein, comprising suspending a denatured protein in a suspension solution to obtain a composition comprising suspended denatured proteins; combining the composition comprising suspended denatured proteins with a solubilization buffer having a pH in the range of 11.5 to 12.8 to thereby obtain a composition comprising solubilized denatured proteins; and combining the composition comprising solubilized denatured proteins with a refold buffer having a pH in the range of 10 to 10.9 to thereby obtain a composition comprising refolded proteins; wherein the method does not include the use of a denaturing agent. 2. The method of claim 1 , wherein the suspension solution consists of water. 3. The method of claim 1 , wherein the denatured proteins are suspended in suspension solution at a ratio of weight (g) of denatured proteins:volume (ml) of suspension solution of 1:1-3. 4. The method of claim 1 , wherein the composition comprising suspended denatured proteins is combined with solubilization buffer at a ratio of weight (g) of denatured proteins:volume (ml) of solubilization buffer of 1:10-30. 5. The method of claim 1 , wherein the composition comprising solubilized denatured proteins is combined with refold buffer at a ratio of volume of solubilization buffer:volume of refold buffer of 1:1-5. 6. The method of claim 1 , wherein the denatured proteins are suspended in suspension solution at a ratio of weight (g) of denatured proteins:volume (ml) of suspension solution of 1:1-3; the composition comprising suspended denatured proteins is combined with solubilization buffer at a ratio of weight (g) of denatured proteins:volume (ml) of solubilization buffer of 1:10-30; and the composition comprising solubilized denatured proteins is combined with refold buffer at a ratio of volume of solubilization buffer:volume of refold buffer of 1:1-5. 7. The method of claim 1 , wherein the suspended denatured proteins and the solubilization buffer are combined for 1-10 minutes prior to being combined with the refold buffer. 8. The method of claim 1 , wherein the composition comprising the solubilized denatured proteins is combined with the refold buffer for 5-60 minutes. 9. The method of claim 1 , wherein the solubilization buffer comprises Arginine. 10. The method of claim 1 , wherein the refold buffer comprises Arginine. 11. The method of claim 1 , wherein the refold buffer comprises an oxidizing agent. 12. The method of claim 1 , wherein the method does not comprise first suspending the denatured protein in a suspension solution. 13. The method of claim 1 , wherein the denatured proteins are in the form of inclusion bodies (IBs). 14. The method of claim 1 , wherein the protein comprises an Fc region. 15. The method of claim 14 , wherein the protein comprises a binding domain that specifically binds to a target protein, and wherein the binding domain is an alternative scaffold binding domain. 16. The method of claim 15 , wherein the alternative scaffold binding domain is a fibronectin based scaffold domain.

Assignees

Inventors

Classifications

  • having a known sequence of two or more amino acids, e.g. glutathione · CPC title

  • C07K1/1136Primary

    by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents · CPC title

  • by redox-reactions involving cystein/cystin side chains · CPC title

  • Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

  • containing domain for protein-protein interaction · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10065987B2 cover?
Provided herein are methods for refolding denatured protein (e.g., from inclusion bodies) that do not require the use of a denaturing agent. Exemplary methods use a high pH for solubilizing denatured protein, followed by a decrease in pH for refolding the proteins.
Who is the assignee on this patent?
Bristol Myers Squibb Co
What technology area does this patent fall under?
Primary CPC classification C07K1/1136. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).